Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

Vascular stabilization biomarker helps optimize timing of anticancer therapies

Angiogenesis, the formation of new blood vessels, is essential for tumor growth. A new study reported in The American Journal of Pathology describes a vascular stabilization biomarker that can visualize blood vessel activity, thus optimizing the timing of anticancer therapies including anti-angiogenics.

9 Apr 2018

Treating metastatic breast cancer with immunotherapy

Breast cancer, in the stage with distant metastases, is an incurable disease with a 5 years survival rate of about 5-10%. Immunotherapy has recently improved survival in metastatic breast cancer patients with breast cancer harboring the expression of HER 2 receptor.

19 Mar 2018

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic Proceedings

29 Jan 2018

Scientists discover new target for anti-angiogenic tumor therapy

Actively growing tumors have a high demand for oxygen and nutrients. Therefore, they stimulate the growth of blood vessels.

23 Jan 2018

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

A randomized trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia 2017 Congress.

20 Nov 2017

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment for these patients in real-time.

27 Oct 2017

Risk factors, symptoms, diagnosis and treatment of ovarian cancer

Ovarian cancer is the 9th most common cancer in women and although it only accounts for approximately 3 percent of cancers in women, it is responsible for the most deaths of any cancer involving the female reproductive tract.

20 Sep 2017

FDA grants approval for new biosimilar to treat multiple types of cancer

The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

14 Sep 2017

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment extends overall survival to at least 15 months in patients with pleural malignant mesothelioma, according to late-breaking results from the MAPS2 trial presented today at the ESMO 2017 Congress in Madrid.

11 Sep 2017

Tumor irradiation may prolong survival of NSCLC patients undergoing novel chemotherapy formulation

Patients with unresectable, or inoperable, lung cancer are often given a dismal prognosis, with low rates of survival beyond a few years.

26 Aug 2017

Study reveals radiation therapy advantage for patients with right-sided colorectal tumors

For patients with colorectal cancer that has metastasized to the liver, having a primary tumor on the left side, as opposed to the right side of the colon, is known to be a significant advantage in terms of treatment response.

3 Jul 2017

Two widely used drugs show effectiveness in treating patients with CRVO-associated macular edema

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion, according to a clinical trial funded by the National Eye Institute, part of the National Institutes of Health.

10 May 2017

Molecular drug imaging likely to benefit children with brain tumors

Brain cancers are difficult to treat, and it can be hard to predict whether a therapy will be effective. When the patient is a child, it's even more important to predict the potential effectiveness of a drug before beginning treatment.

3 May 2017

New biomarker helps better predict survival after surgical removal of colorectal metastases

Liver metastases are formed from cancer cells that have originated in other organs and migrated to the liver via the bloodstream. Colorectal cancer (cancer of the colon/rectum) can be successfully treated by surgical resection of the metastases in combination with chemotherapy.

23 Jan 2017

New techniques and treatments show promise for eliminating retinopathy of prematurity

A mini-symposium published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus provides important insights into new techniques and treatments that show promise for eliminating retinopathy of prematurity (ROP) throughout the world.

18 Jan 2017

Combination treatment may be valuable therapeutic option for HER2-negative metastatic breast cancer

Finding the ideal combination of targeted, hormonal and chemotherapeutic agents to treat HER2-negative metastatic breast cancer has been challenging researchers for decades.

1 Dec 2016

Researchers identify pathway that helps cancer cells to aggressively spread in the brain

Glioblastoma multiforme remains the most common and highly lethal brain cancer and is known for its ability to relapse.

17 Nov 2016

Allergan, Amgen submit BLA for ABP 215 oncology biosimilar medicine to FDA

Amgen and Allergan plc. today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab).

16 Nov 2016

PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

8 Oct 2016